Consort Medical

Leading pharmaceutical manufacturer, Aesica, has appointed Anthony Allcock as Site Operations Director at its site in Queenborough, Kent. Anthony will work closely with the company’s commercial team to exploit the assets offered by Aesica and promote its end-to-end service proposition.

Originally from St Helens, Anthony trained as an engineer and has worked in the chemical and pharmaceutical industry for 30 years, most notably for Glaxo Smith Kline and previously in the FMCG sector. He joins Aesica following ten years at sterile goods manufacturer, Wockhardt, where he was head of manufacturing and engineering at its North Wales site.

Speaking of his appointment Anthony says: “Aesica’s offering within the pharmaceutical industry is vast and it’s an exciting time to be joining the company. The end-to-end service provision is unique within the industry and following the company’s recent acquisition of R5 Pharmaceuticals, we have significantly extended and enhanced our formulations capability, which will enable us to consolidate our portfolio of pharmaceutical and biotechnology clients. Aesica has ambitious plans for future growth in new markets across the UK and indeed the US and my commercial experience will be of benefit to the company as we look to raise further awareness of our rare and proven proposition.”

Aesica supplies Active Pharmaceutical Ingredients, Formulations and Custom Synthesis solutions to a host of the world’s leading medical and pharmaceutical companies and emerging biotechnology organisations.

Its unique offer lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. Furthermore, the long established and proven expertise within the company enables it to provide primary and secondary contract manufacturing services to the highest possible standards. It is this all-encompassing offer and its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.

The company was founded in 2004 and has three sites in the UK, alongside bases in New York, San Diego and Shanghai.